Search

Your search keyword '"Khattak, Sophia"' showing total 11 results
Start Over Author "Khattak, Sophia"
11 results on '"Khattak, Sophia"'

7. Trends in cardiovascular mortality of cancer patients in the US over two decades 1999‐2019

Author

Kobo, Ofer, primary, Khattak, Sophia, additional, Lopez‐Mattei, Juan, additional, Van Spall, Harriette G. C., additional, Graham, Michelle, additional, Cheng, Richard K., additional, Osman, Mohammed, additional, Sun, Louise, additional, Ullah, Waqas, additional, Fischman, David L., additional, Roguin, Ariel, additional, Mohamed, Mohamed O., additional, and Mamas, Mamas A., additional

Published
2021
Full Text
View/download PDF

8. Epidemiological findings on interventional cardiology procedures during the COVID-19 pandemic: A multi-center study

Author

Albani, Stefano, primary, Vinhas, Hugo, additional, Fuertes Ferre, Georgina, additional, Basavarajaiah, Sandeep, additional, Khattak, Sophia, additional, Tzanis, Giorgos, additional, Pizzato, Margherita, additional, Toselli, Marco, additional, Khokhar, Arif A., additional, Musumeci, Giuseppe, additional, and Giannini, Francesco, additional

Published
2021
Full Text
View/download PDF

10. GPVI inhibition: Advancing antithrombotic therapy in cardiovascular disease.

Author

Slater A, Khattak S, and Thomas MR

Subjects
Humans, Animals, Cardiovascular Diseases drug therapy, Cardiovascular Diseases prevention & control, Signal Transduction drug effects, Treatment Outcome, Blood Platelets drug effects, Blood Platelets metabolism, Thrombosis prevention & control, Thrombosis drug therapy, Thrombosis blood, Platelet Aggregation Inhibitors therapeutic use, Platelet Aggregation Inhibitors adverse effects, Platelet Membrane Glycoproteins antagonists & inhibitors, Platelet Membrane Glycoproteins metabolism, Fibrinolytic Agents therapeutic use, Fibrinolytic Agents adverse effects
Abstract

Glycoprotein (GP) VI (GPVI) plays a major role in thrombosis but not haemostasis, making it a promising antithrombotic target. The primary role of GPVI on the surface of platelets is a signalling receptor for collagen, which is one of the most potent thrombotic sub-endothelial components that is exposed by atherosclerotic plaque rupture. Inhibition of GPVI has therefore been investigated as a strategy for treatment and prevention of atherothrombosis, such as during stroke and acute coronary syndromes. A range of specific GPVI inhibitors have been characterized, and two of these inhibitors, glenzocimab and revacept, have completed Phase II clinical trials in ischaemic stroke. In this review, we summarize mechanisms of GPVI activation and the latest progress of clinically tested GPVI inhibitors, including their mechanisms of action. By focusing on what is known about GPVI activation, we also discuss whether alternate strategies could be used to target GPVI., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results